Compare Stocks: SION, RARE, OMER, and MGTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MGTX MeiraGTx	$13.25 +1.5%	$13.10	$6.62 ▼ $15.35	$1.27B	1.27	698,593 shs	941,208 shs
OMER Omeros	$17.87 -3.1%	$15.19	$4.05 ▼ $19.65	$1.29B	2.6	1.46 million shs	2.15 million shs
RARE Ultragenyx Pharmaceutical	$14.51 +0.1%	$23.88	$12.73 ▼ $39.89	$1.43B	0.31	5.41 million shs	13.33 million shs
SION Sionna Therapeutics	$5.96 -17.0%	$22.51	$4.01 ▼ $54.97	$269.46M	0.89	1.30 million shs	3.68 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MGTX MeiraGTx	0.00%	+3.60%	-8.87%	+17.05%	+80.76%
OMER Omeros	0.00%	-2.24%	-4.08%	+73.83%	+340.15%
RARE Ultragenyx Pharmaceutical	0.00%	+1.47%	-42.69%	-47.12%	-49.46%
SION Sionna Therapeutics	0.00%	-24.08%	+7.97%	-84.02%	-73.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MGTX MeiraGTx	$13.25 +1.5%	$13.10	$6.62 ▼ $15.35	$1.27B	1.27	698,593 shs	941,208 shs
OMER Omeros	$17.87 -3.1%	$15.19	$4.05 ▼ $19.65	$1.29B	2.6	1.46 million shs	2.15 million shs
RARE Ultragenyx Pharmaceutical	$14.51 +0.1%	$23.88	$12.73 ▼ $39.89	$1.43B	0.31	5.41 million shs	13.33 million shs
SION Sionna Therapeutics	$5.96 -17.0%	$22.51	$4.01 ▼ $54.97	$269.46M	0.89	1.30 million shs	3.68 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MGTX MeiraGTx	0.00%	+3.60%	-8.87%	+17.05%	+80.76%
OMER Omeros	0.00%	-2.24%	-4.08%	+73.83%	+340.15%
RARE Ultragenyx Pharmaceutical	0.00%	+1.47%	-42.69%	-47.12%	-49.46%
SION Sionna Therapeutics	0.00%	-24.08%	+7.97%	-84.02%	-73.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MGTX MeiraGTx	2.75	Moderate Buy	$26.17	97.48% Upside
OMER Omeros	2.67	Moderate Buy	$38.00	112.65% Upside
RARE Ultragenyx Pharmaceutical	2.48	Hold	$34.42	137.22% Upside
SION Sionna Therapeutics	2.00	Hold	$42.33	610.29% Upside

Current Analyst Ratings Breakdown

Latest SION, RARE, OMER, and MGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$18.00 ➝ $20.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $32.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $39.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$33.00 ➝ $39.00
9/15/2026	SION Sionna Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$5.00 ➝ $6.00
9/11/2026	MGTX MeiraGTx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/4/2026	RARE Ultragenyx Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$28.00 ➝ $19.00
9/4/2026	RARE Ultragenyx Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$43.00 ➝ $32.00
9/3/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/3/2026	RARE Ultragenyx Pharmaceutical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
9/3/2026	RARE Ultragenyx Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$77.00 ➝ $28.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MGTX MeiraGTx	$81.39M	15.63	N/A	N/A	($0.07) per share	-189.29
OMER Omeros	N/A	N/A	$1.87 per share	9.55	($1.71) per share	N/A
RARE Ultragenyx Pharmaceutical	$673M	2.13	N/A	N/A	($0.83) per share	-17.48
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	$6.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MGTX MeiraGTx	-$114.20M	$0.71	18.66	N/A	N/A	19.87%	283.85%	29.39%	11/12/2026 (Estimated)
OMER Omeros	-$3.35M	$1.28	13.96	15.81	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-44.40%	11/3/2026 (Estimated)
SION Sionna Therapeutics	-$75.27M	-$2.18	N/A	N/A	N/A	N/A	-32.94%	-31.08%	N/A

Latest SION, RARE, OMER, and MGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MGTX MeiraGTx	-$0.4583	$1.71	+$2.1683	$1.71	$0.70 million	$321.43 million
8/13/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/6/2026	Q2 2026	SION Sionna Therapeutics	-$0.64	-$0.66	-$0.02	-$0.66	N/A	N/A
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MGTX MeiraGTx	0.46	3.76	3.76
OMER Omeros	N/A	1.95	1.94
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56
SION Sionna Therapeutics	N/A	20.05	20.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MGTX MeiraGTx	67.48%
OMER Omeros	48.79%
RARE Ultragenyx Pharmaceutical	97.67%
SION Sionna Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
MGTX MeiraGTx	7.40%
OMER Omeros	10.50%
RARE Ultragenyx Pharmaceutical	5.20%
SION Sionna Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MGTX MeiraGTx	393	96.04 million	88.94 million	Optionable
OMER Omeros	175	72.39 million	64.79 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable
SION Sionna Therapeutics	59	45.21 million	42.91 million	N/A

SION, RARE, OMER, and MGTX Headlines

Recent News About These Companies

Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $42.22 Consensus Target Price from Analysts

September 18 at 3:44 AM | americanbankingnews.com

Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?

September 17 at 6:36 PM | finance.yahoo.com

A Biotech Company Had $268 Million in Cash. After a Failed Drug Trial, It Announced a 46 Percent Workforce Cut

September 17 at 1:35 PM | inc.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 17 at 10:00 AM | prnewswire.com

Sionna Therapeutics (NASDAQ:SION) Stock Price Expected to Rise, Wedbush Analyst Says

September 17 at 1:30 AM | americanbankingnews.com

Stifel Nicolaus Keeps Their Hold Rating on Sionna Therapeutics, Inc. (SION)

September 16, 2026 | theglobeandmail.com

Waltham Biotech Sionna Cuts 46% of Staff After $2B Stock Collapse

September 16, 2026 | hoodline.comH

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

September 16, 2026 | finance.yahoo.com

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

September 16, 2026 | zacks.com

Brokerages Set Sionna Therapeutics, Inc. (NASDAQ:SION) Price Target at $42.22

September 16, 2026 | defenseworld.netD

FDA clears first generic radioligand drug; Sionna turns to layoffs

September 15, 2026 | biopharmadive.comB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 15, 2026 | globenewswire.com

Sionna Advances New CF Combo To Phase 2a After SION-719 Setback, Cuts Workforce 46%; Stock Down

September 15, 2026 | rttnews.com

Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail

September 15, 2026 | fiercebiotech.comF

Sionna Therapeutics (NASDAQ:SION) Given New $6.00 Price Target at Wedbush

September 15, 2026 | marketbeat.com

Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript

September 15, 2026 | seekingalpha.com

Sionna Therapeutics (SION) Reiterated at Market Perform by Citizens Amid Ph2a Trial Issues

September 15, 2026 | streetinsider.com

Sionna Therapeutics to Cut 46% of Staff to Focus on Cystic Fibrosis Drug Development

September 14, 2026 | marketwatch.com

Sionna Therapeutics Restructures to Focus on Dual Combination

September 14, 2026 | tipranks.com

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

September 14, 2026 | globenewswire.com

Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of "Hold" by Brokerages

September 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SION, RARE, OMER, and MGTX Company Descriptions

MeiraGTx NASDAQ:MGTX

$13.25 +0.20 (+1.53%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.24 -0.01 (-0.04%)

As of 09/18/2026 07:30 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Omeros NASDAQ:OMER

$17.87 -0.58 (-3.14%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$18.04 +0.16 (+0.92%)

As of 09/18/2026 07:43 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Ultragenyx Pharmaceutical NASDAQ:RARE

$14.51 +0.01 (+0.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.55 +0.04 (+0.25%)

As of 09/18/2026 07:59 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Sionna Therapeutics NASDAQ:SION

$5.96 -1.22 (-16.99%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.03 +0.07 (+1.24%)

As of 09/18/2026 07:50 PM Eastern

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SION, RARE, OMER, and MGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SION, RARE, OMER, and MGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SION, RARE, OMER, and MGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SION, RARE, OMER, and MGTX Company Descriptions

MeiraGTx NASDAQ:MGTX

Omeros NASDAQ:OMER

Ultragenyx Pharmaceutical NASDAQ:RARE

Sionna Therapeutics NASDAQ:SION

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SION, RARE, OMER, and MGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SION, RARE, OMER, and MGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SION, RARE, OMER, and MGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SION, RARE, OMER, and MGTX Company Descriptions

MeiraGTx NASDAQ:MGTX

Omeros NASDAQ:OMER

Ultragenyx Pharmaceutical NASDAQ:RARE

Sionna Therapeutics NASDAQ:SION

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools